From Yahoo Finance: 2025-05-27 13:03:00

Citizens JMP analyst Jason Butler reaffirmed a Buy rating on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) with a price target of $19.00 on May 27. The company’s fiscal Q1 2025 results showed positive operations, with net revenue hitting $20.4 million, driven by product net revenue of $17.2 million, beating earnings expectations with an EPS of $-0.06. ZVRA announced the sale of its Pediatric Rare Disease Priority Review Voucher for $150 million on April 7, positioning the company to strengthen its balance sheet and support development programs. ZVRA focuses on developing therapies for rare neurological and sleep conditions.



Read more at Yahoo Finance: Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT